Skip to main content

Master of Public Health

Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Pcsk9 Inhibitor Therapeutics.

AUTHORS

Underberg JA , Blaha MJ , Msn EJJ , Jones PH , . The American journal of medicine. 2017 7 21; ().

ABSTRACT

This educational content was derived from live, satellite symposium at the American College of Physicians (ACP) Internal Medicine Meeting 2017 in San Diego, California (online at http://courses.elseviercme.com/acp/702e). This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.

This educational content was derived from live, satellite symposium at the American College of Physicians (ACP) Internal Medicine Meeting 2017 in San Diego, California (online at http://courses.elseviercme.com/acp/702e). This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.

Tags: